A Dual-Viral Delivery Platform Enables Efficient Site-Specific Integration of Therapeutic-Length Genes in Human Primary Stem Cells
Human Gene Therapy · 2026
DOI: 10.1177/10430342261453040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2026. Verfasst von Zhu-Ying Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Lentivirus, Genetic Vectors, Gene Transfer Techniques, Gene Editing. Die Arbeit nennt 64 Literaturangaben. Gefördert von: the Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project, the National Natural Science Foundation of China, the Haihe Laboratory of Cell Ecosystem Innovation Fund.
Abstract (Originalsprache)
Site-specific integration of large genes in human primary stem cells remains a significant challenge in gene therapy, particularly for treating multiallelic diseases. Gene editing efficiency in primary stem cells is heavily influenced by the delivery strategy, which often faces issues with programmability, efficiency, and specificity. Here, we developed a dual-viral delivery system, targeted integration via virus-like particles and integrase-deficient lentivirus (TIVID). This system combines virus-like Cas9 edit particles for delivering Cas9/sgRNA ribonucleoprotein complexes and integrase-deficient lentiviral vectors for delivering HDR donor templates. The TIVID system achieves a knock-in efficiency of 65% ± 5% in human induced pluripotent stem cells (iPSCs). In erythroid progenitor HUDEP2 cells, TIVID mediates precise integration of a 7.1 kb HBB-GFP cassette (from cut site to cut site) at the AAVS1 locus with 20% efficiency and stable expression. Crucially, we demonstrate that TIVID overcomes stringent packaging constraints to deliver an approximately 6 kb full-length HBB therapeutic cassette into primary human CD34 + hematopoietic stem and progenitor cells. This platform achieved 5–10% targeted integration efficiency and preserved robust lineage-specific differentiation capacity, demonstrating its potential for treating β-thalassemia and other multiallelic disorders. In head-to-head comparisons, TIVID outperformed lentivirus-derived nanoparticles (∼50% vs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Tianjin Institutes of Health Science, Tianjin, China.
ORCID-Profile: Zhu-Ying Gao
Förderung
- the Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project
- the National Natural Science Foundation of China
- the Haihe Laboratory of Cell Ecosystem Innovation Fund
- the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences
- the Postdoctoral Fellowship Program of CPSF
- the CAMS Fundamental Research Funds for Central Research Institutes
- the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
- the National Key Research and Development Program of China
Zitieren
APA
Gao, Z. Y., Shen, T. L., Cheng, C. Y., Sun, Y. D., Zhang, L. M., Zhang, J. P., & Zhang, X. B. (2026). A Dual-Viral Delivery Platform Enables Efficient Site-Specific Integration of Therapeutic-Length Genes in Human Primary Stem Cells. Human Gene Therapy. https://doi.org/10.1177/10430342261453040
Vancouver
Gao ZY, Shen TL, Cheng CY, Sun YD, Zhang LM, Zhang JP, et al. A Dual-Viral Delivery Platform Enables Efficient Site-Specific Integration of Therapeutic-Length Genes in Human Primary Stem Cells. Human Gene Therapy. 2026. doi:10.1177/10430342261453040
BibTeX
@article{Gao2026,
author = {Gao, Zhu-Ying and Shen, Tian-Lai and Cheng, Chong-Yan and Sun, Yi-Dan and Zhang, Li-Ming and Zhang, Jian-Ping and Zhang, Xiao-Bing},
title = {A Dual-Viral Delivery Platform Enables Efficient Site-Specific Integration of Therapeutic-Length Genes in Human Primary Stem Cells},
journal = {Human Gene Therapy},
year = {2026},
doi = {10.1177/10430342261453040}
}
EUVIMED